- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Aktie von Genenta Science schießt nach Update zu Glioblastom-Studie in die Höhe | 10 | Investing.com Deutsch | ||
| GENENTA SCIENCE Aktie jetzt für 0€ handeln | |||||
| Mo | GENENTA SCIENCE SPA: Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial | 167 | GlobeNewswire (Europe) | MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic... ► Artikel lesen | |
| 28.10. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.10. | Aktie von Genenta Science stürzt nach 15-Millionen-Dollar-Kapitalerhöhung ab | 13 | Investing.com Deutsch | ||
| 27.10. | Genenta Science stock plunges after $15 million ADS offering | 2 | Investing.com | ||
| 27.10. | Genenta Science jumps on $15M direct offering | 3 | Seeking Alpha | ||
| 27.10. | Genenta Science raises $15 million in ADS offering at $3.50 per share | 4 | Investing.com | ||
| 27.10. | GENENTA SCIENCE SPA: Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares | 2 | GlobeNewswire (USA) | ||
| 24.10. | Genenta Science Stock Jumps 85% On Strategic Collaboration With Anemocyte | 10 | RTTNews | ||
| 24.10. | Genenta Science stock soars on strategic LVV Plasmid DNA collaboration | 5 | Investing.com | ||
| 24.10. | Genenta and Anemocyte partner on lentiviral vector plasmid DNA tech | 17 | Investing.com | ||
| 24.10. | GENENTA SCIENCE SPA: Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production | 1.500 | GlobeNewswire (Europe) | MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today... ► Artikel lesen | |
| 10.10. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 03.10. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.09. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.08. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.07. | Genenta Science-Aktie behält Kaufempfehlung - Temferon vielversprechende Ergebnisse bei GBM zeigt | 3 | Investing.com Deutsch | ||
| 02.07. | Genenta Science stock maintains Buy rating as Temferon shows promise in GBM | 1 | Investing.com | ||
| 01.07. | GENENTA SCIENCE SPA: Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals | 1 | GlobeNewswire (USA) | ||
| 08.05. | D.Boral Capital: Genenta Science Announces Participation in the D. Boral Capital Inaugural Global Conference | 218 | Newsfile | Milan, Italy and New York, New York--(Newsfile Corp. - May 8, 2025) - Genenta Science, SpA (NASDAQ: GNTA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 74,96 | 0,00 % | Guggenheim bestätigt Kaufempfehlung für Arcellx: Aktuelle Kursschwäche übertrieben | ||
| ARCUTIS BIOTHERAPEUTICS | 30,760 | 0,00 % | Why Shares in Arcutis Biotherapeutics Surged Again This Week | ||
| DISC MEDICINE | 94,11 | 0,00 % | Jefferies bestätigt Kaufempfehlung für Disc Medicine angesichts wichtiger Katalysatoren | ||
| DYNE THERAPEUTICS | 21,670 | 0,00 % | Why Dyne Therapeutics Stock Was Crushing it This Week | ||
| PRAXIS PRECISION MEDICINES | 191,36 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| AVIDITY BIOSCIENCES | 71,18 | 0,00 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| IMMUNOVANT | 23,320 | 0,00 % | Immunovant, Inc. - 8-K, Current Report | ||
| OLEMA PHARMACEUTICALS | 25,055 | 0,00 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 8,170 | 0,00 % | Relay Therapeutics: Citizens bestätigt "Market Outperform"-Rating und Kursziel von 12 US-Dollar | ||
| RAPPORT THERAPEUTICS | 28,320 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,320 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 12,930 | 0,00 % | Vielversprechende AML-Daten: BTIG erhöht Kursziel für Cullinan Oncology auf 38 US-Dollar | ||
| DAY ONE BIOPHARMACEUTICALS | 8,880 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases | Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid... ► Artikel lesen | |
| ARVINAS | 11,770 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,540 | 0,00 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So |
GENENTA SCIENCE SPA ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,030 (-1,97 %) liegt der Kurs bei 1,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENENTA SCIENCE SPA ADR finden Sie auf Wallstreet Online.